Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. - Wikidata - awgldk - TriplyDB

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

http://www.wikidata.org/entity/Q45855065

about

Rituximab for treating inhibitors in people with inherited severe hemophilia Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice Animal models of hemophilia A review of current methods for assessing hemostasis in vivo and introduction to a potential alternative approach.Multimerization of peptide mimotopes for blocking of factor VIII neutralizing antibodies.Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.Novel therapies for immune tolerance in haemophilia A.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Haemophilia therapies.International workshop on immune tolerance induction: consensus recommendations.Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease.Mild/moderate haemophilia A: new insights into molecular mechanisms and inhibitor development.Inhibitors in mild/moderate haemophilia A: two case reports and a literature review.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor Mice Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells The use of a single von Willebrand factor-containing, plasma-derived FVIII product in hemophilia A immune tolerance induction: the US experience.Immune tolerance induction in patients with severe hemophilia with inhibitors: expert panel views and recommendations for clinical practice.The reversal of inhibitors in congenital hemophilia.Inhibitor eradication with rituximab in haemophilia: where do we stand?Inhibitors - genetic and environmental factors.Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.Molecular and clinical predictors of inhibitor risk and its prevention and treatment in mild hemophilia A.Rituximab for treating inhibitors in people with inherited severe hemophilia.Factor VIII inhibitors: Advances in basic and translational science.Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor.Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.Rituximab for adolescents with haemophilia and high titre inhibitors.Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.Rituximab treatment of mild haemophilia A with inhibitors: a proposed treatment protocol.Rituximab as first-line treatment for the management of adult patients with non-severe hemophilia A and inhibitors.Refractory lupus nephropathy and acquired Factor VIII and IX deficiencies in a patient with systemic lupus erythematosus treated with rituximab.Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.Identical but different: haemophilia B in monozygotic twins with inhibitor in one brother and subsequent successful immune tolerance induction.Rituximab for treatment of inhibitors in haemophilia A. A Phase II study.Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.Dexamethasone promotes durable factor VIII -specific tolerance in hemophilia A mice via thymic mechanisms.

P2860

Q24186623-D13CD7F0-3848-4AAF-AC05-148C7A65FE44 Q24195006-8766B9BC-CDB3-4506-80D5-8A521583EB58 Q24202592-C7549E14-C887-46F4-ABEF-329DC3CA2C2D Q24302335-1608087C-4F78-4A3A-A85E-94BF1BA98482 Q27012571-7656BEEA-29D0-49B6-ADC0-EE1863370BD0 Q30442996-5986D254-4FF2-4CC6-8D8E-C429AB2864DE Q33469732-3284A94D-7714-4637-B6AE-D0294648966D Q34707338-57946C8B-0A87-4CD7-A8A9-C86087F10BBA Q36480548-E72930CB-4D2A-46F7-B23A-4FD3EE4A4B6A Q36661858-A74299ED-3386-4FC0-9E21-D41E2719E6BF Q36707550-3595F299-CFDE-484A-A7E6-82D4F81A17E4 Q36810282-87FCBA58-1D6F-4EF3-BD9C-7E2BE01A4A60 Q36861097-253B0104-7A63-4EA7-ABE8-7ACEB272B43D Q37012107-E68AF425-654E-46B0-813E-F2359FC7FDA7 Q37176534-76A55AAB-7C8C-4C16-825B-E93408A1370F Q37244126-6F6A88B1-4161-47A9-BD71-C1623D741AB9 Q37434315-A0EA1D76-21A6-4876-BBD0-58BD00A0D147 Q37803130-8769DF2E-BF25-4621-9396-971CCC441CD0 Q37924970-20958F4A-8EB6-4F9E-A591-C9E077A280C7 Q37977140-987D93F6-C362-407E-A591-C1A4A0D1CB70 Q38077139-E61A50C9-DCCC-496D-A23B-19F96793A082 Q38195908-A6EBAAEF-5D5A-443C-B336-3B5BC35E63D9 Q38206856-0942B8EA-37E6-44C1-AF83-7AC45E2F6FC5 Q38222574-6543F004-054A-45FC-9F07-21A8F01D43B7 Q38241445-44C80C23-C231-4AEC-83BE-17A7D5E4C01B Q38661525-57EE4C0F-97A2-4B0B-A7BC-ACFC9BE88915 Q39266287-1D2DCF1B-4714-4FCE-9807-BFC596F5DAD0 Q41924275-DA4281CE-A69B-4A92-90B3-FCB74F4A8AC0 Q43007265-3514696F-9C36-4DF2-B68B-B084CD985099 Q45838031-1E4E572A-B593-4A70-AC1E-962942241CE9 Q45857818-139BED63-D647-4840-8289-84A712C9BF34 Q45859168-F36020E6-C9DB-4D38-AC7E-F8E390FD70E6 Q45863589-0A2D621C-014A-4DA7-B4B9-FE7DC2463093 Q45863855-03407736-4FDD-47CA-B6BD-5220E71F823D Q45871306-A04B6E0F-E82D-4B48-A46F-15431D346350 Q45875675-921BDDAD-9EBA-481E-A366-1FCC49628EFC Q45879318-ADCE6333-C0AA-44E4-ADD1-8A90559F74BD Q49866575-A731A9DD-8A50-48A1-AF7D-8EBEA789DBE0 Q50622853-AFB7C559-F971-4182-B6B0-478213813304 Q52315048-D233BCC1-A0C5-4A91-8910-AE43FFDD27FD

P2860

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

http://www.wikidata.org/entity/Q45855065

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@en

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@nl

type

label

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@en

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@nl

prefLabel

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@en

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@nl

P1433

Q45855065-A84C26DB-6D36-4E3E-A268-96932F66A674

P1476

Q45855065-BEEDE3D5-32EA-428C-8BA2-106B8C394069

P2093

Q45855065-423527EB-A53F-4697-A796-CB4BA78E9844

Q45855065-47BA4E30-BFB0-45AA-817C-63E39DCDE267

Q45855065-48E0992B-8FD1-44FD-85B1-81B490015871

Q45855065-5169A2A4-9679-4F26-BF60-8D7B26451BF7

Q45855065-554BE861-B031-4325-BEFC-8754CEBE5568

Q45855065-5BB9A557-DBAD-40B5-9648-83D963B4B282

Q45855065-7C228C40-E28A-41BF-8491-41F084720A9C

Q45855065-9339FFA6-4899-4125-B6B0-4A07AD2C2FC7

Q45855065-A213F05C-3778-4029-8311-A512AF5735DE

P2860

Q45855065-14EDAB8A-2228-40AC-916D-096A5C0E0E0E

Q45855065-21198782-CDA7-4250-87F3-FFC82A55997D

Q45855065-40FBEA02-C5CF-491B-8155-C1B5E5FF8D63

Q45855065-4BBC89D8-17D2-4C54-912F-C6DB3D522157

Q45855065-4F831051-D646-4A0D-AAD7-469928AB7ADF

Q45855065-5289E694-6366-4D86-9B4C-4E872B3C42D1

Q45855065-60E9B077-6A76-40DF-B062-0F705CD14D66

Q45855065-7A0062C8-9CB3-4F5E-A4B8-E45DFDE56A3D

Q45855065-7F21FDFA-5E31-4FC8-8FEF-D2930449C7FD

Q45855065-82DA8359-3F5F-4ED2-97C8-E33F4A27836D

P304

Q45855065-C0F7778D-4E7D-4501-9599-DD31F6BDD41D

P31

Q45855065-3D8B9A7C-FE59-476C-9D51-59AAD2339F89

P356

Q45855065-5B2F18C6-95B0-4B9D-A45B-7D045B40555B

P433

Q45855065-FACFC723-038F-4347-B496-DF79E33E52B7

P478

Q45855065-2C0C6D6B-1A51-47AD-8914-02DBD322A18C

P577

Q45855065-1693E01B-D58B-494F-A4BE-E54F6F8FE861

P5875

Q45855065-A81FDB5B-C124-4FF4-A2B6-54A6EF493C21

P698

Q45855065-D0C936D1-1E70-4645-BC5E-13FA37522715

P356

J.1365-2516.2005.01170.X

P1433

P1476

Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.

@en

P2093

A M Stain

http://www.w3.org/2001/XMLSchema#string

E Grunebaum

http://www.w3.org/2001/XMLSchema#string

G E Rivard

http://www.w3.org/2001/XMLSchema#string

Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada

http://www.w3.org/2001/XMLSchema#string

J St Louis

http://www.w3.org/2001/XMLSchema#string

M Carcao

http://www.w3.org/2001/XMLSchema#string

M-C Poon

http://www.w3.org/2001/XMLSchema#string

S Lacroix

http://www.w3.org/2001/XMLSchema#string

V S Blanchette

http://www.w3.org/2001/XMLSchema#string

P2860

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children

Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic autoimmune thrombocytopenia and neutropenia.

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.

Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.

Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Clinical applications of anti-CD20 antibodies.

Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients.

Rituximab: clinical development and future directions.

Comparative pharmacokinetic studies in haemophilia.

Rituximab: expanding role in therapy for lymphomas and autoimmune diseases.

P304

7-18

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2516.2005.01170.X

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2006-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7363380

http://www.w3.org/2001/XMLSchema#string

P698

16409170

http://www.w3.org/2001/XMLSchema#string